secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001159036-25-000049
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme prices $1.3B convertible notes offering; to repurchase ~$1.02B of existing 2027/2028 notes
--------------------------------------------------------------------------------

- Priced $650M of 0% convertible notes due 2031 and $650M of 0.875% notes due 2032; initial purchasers have 13-day option for additional $200M.
- Initial conversion price of ~$87.20/share, a 27.5% premium over the $68.39 closing price on Nov. 6, 2025.
- Net proceeds of ~$1.274B ($1.47B if option exercised); ~$1.019B to repurchase outstanding 0.25% 2027 and 1.00% 2028 notes.
- Entered into capped call transactions with cap price of $136.78/share to reduce potential dilution upon conversion.
- Expected to close offering on November 12, 2025; remainder of proceeds for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000049/0001159036-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000049/halo-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer